Skip to content

Effect of Allopurinol on Blood Lipids and Drug Adherence in Dialysis Patients

Effectiveness of Allopurinol on Lipid Profile and Medication Adherence in Hemodialysis Patients with End-Stage Renal Disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260425069150N1
Enrollment
180
Registered
2026-05-17
Start date
2025-09-23
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease (ESRD) undergoing hemodialysis with hyperuricemia. End stage renal disease

Interventions

Intervention 1: Intervention group one: Receives Allopurinol 100 mg orally daily for three months. Also receives an educational intervention consisting of 4 sessions (each 45-60 minutes) using pamphle

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient has at least three months of regular hemodialysis history. Patient does not use uric acid-lowering medications. Patient does not use diuretics or ARBs (angiotensin receptor blockers). Patient does not have an acute gout attack. Hyperuricemia: serum uric acid =7 mg/dL in men and =6 mg/dL in women.

Exclusion criteria

Exclusion criteria: Inability to give informed consent. Pregnancy or breastfeeding. Active malignancy undergoing chemo- or radiotherapy. Severe hypersensitivity to allopurinol Use of azathioprine or 6-mercaptopurine.

Design outcomes

Primary

MeasureTime frame
Changes in mean serum total cholesterol level (mg/dL) in patients before and three months after the intervention. Timepoint: Before the intervention (baseline) and three months after the start of the intervention. Method of measurement: For lipid profile variables (total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein), blood biochemical testing using standard laboratory kits is used. For medication adherence behavior, the End-Stage Renal Disease Adherence Questionnaire is used.

Secondary

MeasureTime frame
Changes in mean serum creatinine level (mg/dL) in patients before and three months after the intervention. Timepoint: Before the intervention (baseline) and three months after the start of the intervention. Method of measurement: For uric acid, creatinine, and albumin, blood testing using standard biochemical kits is performed in the laboratory of Shahid Beheshti Hospital in Hamadan.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTahereh Abbasi gravand

Hamedan University of Medical Sciences

t.abbasi@umsha.ac.ir+98 81 3838 0032

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026